DrugPatentWatch Database Preview
VRAYLAR Drug Profile
When do Vraylar patents expire, and when can generic versions of Vraylar launch?
Vraylar is a drug marketed by Allergan Sales Llc and is included in one NDA. There are two patents protecting this drug.
This drug has seventy-nine patent family members in thirty-six countries.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.
Summary for VRAYLAR
| International Patents: | 79 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 20 |
| Clinical Trials: | 2 |
| Patent Applications: | 18 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for VRAYLAR |
| DailyMed Link: | VRAYLAR at DailyMed |
Generic Entry Opportunity Date for VRAYLAR
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VRAYLAR
| Drug Class | Atypical Antipsychotic |
Synonyms for VRAYLAR
| 1083076-69-0 |
| 3-((1R,4r)-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-1,1-dimethylurea hydrochloride |
| AK341028 |
| AKOS027338713 |
| Cariprazine (hydrochloride) |
| Cariprazine HCl |
| CARIPRAZINE HYDROCHLORIDE |
| Cariprazine hydrochloride (JAN/USAN) |
| Cariprazine hydrochloride [USAN] |
| cariprazine monohydrochloride |
| cariprazine.HCl |
| CHEBI:90932 |
| CHEMBL2024517 |
| CS-1570 |
| D09876 |
| EX-A1644 |
| FT-0701196 |
| HY-14763A |
| KQD7C255YG |
| KS-00000640 |
| MFCD26142670 |
| MolPort-044-723-876 |
| N'-(Trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexyl)-N,N-dimthylurea monohydrochloride |
| N'-(trans-4-{2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl}cyclohexyl)-N,N-dimethylurea hydrochloride |
| RGH-188 HCL |
| SCHEMBL183803 |
| SCHEMBL183804 |
| UNII-KQD7C255YG |
| Urea, N'-(trans-4-(2-(4-(2,3-dichlorophenyl)-1-piperazinyl)ethyl)cyclohexyl)-N,N- dimethyl-, hydrochloride (1:1) |
| Vraylar (TN) |
US Patents and Regulatory Information for VRAYLAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Sales Llc | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-001 | Sep 17, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Allergan Sales Llc | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-002 | Sep 17, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-001 | Sep 17, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-003 | Sep 17, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Allergan Sales Llc | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-002 | Sep 17, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for VRAYLAR
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 1663996 | ➤ Sign Up |
| Slovenia | 2155696 | ➤ Sign Up |
| Tunisia | 2009000458 | ➤ Sign Up |
| Georgia, Republic of | P20125522 | ➤ Sign Up |
| Hungary | 0302451 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for VRAYLAR
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017000083 | Germany | ➤ Sign Up | PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 20170713 |
| 0913 | Netherlands | ➤ Sign Up | PRODUCT NAME: CARIPRAZINE, OPTIONEEL IN DE VORM VAN EEN ZOUT, WAARONDER CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170717 |
| /2017 | Austria | ➤ Sign Up | PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZIN HYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 (MITTEILUNG) 20170717 |
| 2017 00042 | Denmark | ➤ Sign Up | PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717 |
| 2017027 | Lithuania | ➤ Sign Up | PRODUCT NAME: KARIPRAZINAS, DRUSKOS FORMOS, KONKRECIAI JO HIDROCHLORIDO DRUSKOS FORMOS, T.Y. KARIPRAZINO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/17/1209 20170713 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
